Hospital admissions among patients with T2D taking basal insulin only were reduced by 67% one year after beginning treatment with the CGM system.
Blood pressure-lowering therapy reduced the risk of major CV events in persons with and without type 2 diabetes, according to an individual participant-level data meta-analysis.
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.
A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.
ADA 2022: Patients with T2D who received a treatment intervention powered by artificial intelligence achieved a remission rate of more than 80%.
ADA 2022: "Breakthrough" findings may help to address the unmet need for additional treatment options for young patients with type 2 diabetes.
ADA 2022: Younger age, insulin use, higher HbA1c, and higher diabetes distress were found to be associated with CGM uptake in prospective study.
ADA 2022: In a new literature review, 43% of studies included identified diabetes as a potent risk for developing post-acute sequelae of COVID-19.
ADA 2022: Tirzepatide led overall to weight loss of up to 22.5% of baseline body weight with persons taking the 15 mg dose losing an average of 52 pounds.
Compare, contrast, price shop, prescribe. DiabetesWise Pro developer Korey Hood, PhD, highlights the tool all primary care clinicians should try.